Has Victoria Stella, MD received payments from drug or device companies?

Yes. Drug and device makers reported $649 in general payments to Victoria Stella, MD across 20 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Victoria Stella, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Victoria Stella, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Victoria Stella, MD

Family Medicine · Reading, PANPI 1578678884

Payments from drug & device makers

$649in general payments, 2019–2025

Across 20 payments — averaging $32.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim$124
Alnylam Pharmaceuticals Inc.$122
AstraZeneca$101
Novartis$92
Novo Nordisk$56
Dynavax Technologies Corporation$53
plus $101 from 4 others

What the payments were for

Food & beverage$62496%
Education$254%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim	1	$124
Alnylam Pharmaceuticals Inc.	1	$122
AstraZeneca(2 entities)	5	$101
Novartis	4	$92
Novo Nordisk	2	$56
Dynavax Technologies Corporation	2	$53
GSK	2	$36
Lilly USA, LLC	1	$25
Astellas Pharma US Inc	1	$21
Merck	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

JARDIANCE$124
GIVLAARI$122

How this compares

$649 in reported general payments places this provider in the 60th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$59,111

Medicare patients

219

Services billed

595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
TrulicityDulaglutide	284	$301,074
JanuviaSitagliptin Phosphate	266	$271,419
JardianceEmpagliflozin	141	$123,435
Breo ElliptaFluticasone/Vilanterol	145	$61,433
EliquisApixaban	70	$60,225
FarxigaDapagliflozin Propanediol	74	$54,746
LinzessLinaclotide	73	$50,317
OzempicSemaglutide	49	$48,834
TradjentaLinagliptin	66	$48,005
XareltoRivaroxaban	38	$44,426
CreonLipase/Protease/Amylase	13	$35,688
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	54	$34,632
Fluticasone-SalmeterolFluticasone Propion/Salmeterol	143	$31,031
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	259	$25,798
Albuterol Sulfate HfaAlbuterol Sulfate	977	$25,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Lilly USA, LLCTrulicity	$25	$301,074284 claims
MerckJanuvia, Janumet, Janumet Xr	$20	$290,018292 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat	$124	$181,372228 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta, Anoro Ellipta	$36	$113,847247 claims
AstraZenecaFarxiga, Symbicort	$101	$65,356114 claims
Novo NordiskOzempic	$56	$48,83449 claims
NovartisEntresto	$92	$20,53125 claims
Astellas Pharma US IncMyrbetriq	$21	$5,87113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,967 family medicine providers in Pennsylvania.